To register a large number of patients with the diagnosis of a BCR-ABL 1- negative myeloid neoplasm (according to WHO 2008 / 2016 classification) in participating centers To store samples from all patients (e.g. bone marrow aspirate, peripheral blood, plasma, and buccal swap, skin biopsy samples in exceptional cases) To perform morphologic and genetic analyses To assess clinical characteristics and outcome data using a defined catalogue containing clinically relevant variables To assess biological disease features and correlate with clinical outcome data (prognostic and predictive markers) To assess quality of life
To register a large number of patients with the diagnosis of a BCR-ABL 1- negative myeloid neoplasm (according to WHO 2008 / 2016 classification) in participating centers To store samples from all patients (e.g. bone marrow aspirate, peripheral blood, plasma, and buccal swap, skin biopsy samples in exceptional cases) To perform morphologic and genetic analyses To assess clinical characteristics and outcome data using a defined catalogue containing clinically relevant variables To assess biological disease features and correlate with clinical outcome data (prognostic and predictive markers) To assess quality of life
Study Type
OBSERVATIONAL
Enrollment
2,172
Hämatologische Onkologie Praxis Augsburg
Augsburg, Germany
RECRUITINGKlinikum Augsburg
Augsburg, Germany
RECRUITINGHelios Klinikum, Bad Saarow
Bad Saarow, Germany
RECRUITINGKlinikum Mittelbaden
Baden-Baden, Germany
Treatment decision
Treatment decision (watch and wait, standard, investigational)
Time frame: 25 years
Response
Response of treatment
Time frame: 25 years
Overall survival
Survival over the whole study duration
Time frame: 25 years
Progression-free-survival
Survival without any progression
Time frame: 25 years
Duration of response
Duration of response over the whole study duration
Time frame: 25 years
Quality of life assessed by the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF Protocol 5/25/11, EORTC QLQ-C30, FACT-Lym (Fassung 4)), supplemented by information on self-assessed concomitant diseases and demographics.
Quality of life assessed by the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF Protocol 5/25/11, EORTC QLQ-C30, FACT-Lym (Fassung 4)), supplemented by information on self-assessed concomitant diseases and demographics.
Time frame: 25 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
MVZ Klinikum Coburg
Coburg, Germany
RECRUITINGDonauwörth, Onko-Medeor
Donauwörth, Germany
RECRUITINGOnkologie, BAG, Dresden
Dresden, Germany
RECRUITINGOnkologie Erding
Erding, Germany
RECRUITINGUniversitätsklinikum Freiburg
Freiburg im Breisgau, Germany
RECRUITINGAlb Fils Kliniken Göppingen
Göppingen, Germany
RECRUITING...and 20 more locations